Porous particles comprising excipients for deep lung delivery

Details Porous particles comprising excipients for deep lung delivery Porous particles comprising excipients for deep lung delivery

2004-04-06

2008-10-14

Richter, Johann (Department: 1616)

Drug, bio-affecting and body treating compositions

Effervescent or pressurized fluid containing

Organic pressurized fluid

C424S489000, C514S002600, C514S023000, C514S04400A, C514S075000, C514S149000, C514S150000, C514S152000, C514S155000, C514S156000, C514S183000, C514S492000, C514S506000, C514S553000

Reexamination Certificate

active

07435408

ABSTRACT:
Improved porous particles for drug delivery to the pulmonary system, and methods for their synthesis and administration are provided. In a preferred embodiment, the porous particles are made of a biodegradable material and have a mass density less than 0.4 g/cm3/. The particles may be formed of biodegradable materials such as biodegradable polymers. For example, the particles may be formed of a functionalized polyester graft copolymer consisting of a linear a-hydroxy-acid polyester backbone having at least one amino acid group incorporated therein and at least one poly(amino acid) side chain extending from an amino acid group in the polyester backbone. In one embodiment, porous particles having a relatively large mean diameter, for example greater than 5 μm, can be used for enhanced delivery of a therapeutic agent to the alveolar region of the lung. The porous particles incorporating a therapeutic agent may be effectively aerosolized for administration to the respiratory tract to permit systemic or local delivery of wide variety of therapeutic agents.

REFERENCES:
patent: 4161516 (1979-07-01), Bell
patent: 4272398 (1981-06-01), Jaffe
patent: 4590206 (1986-05-01), Forrester et al.
patent: 4741872 (1988-05-01), De Luca et al.
patent: 4818542 (1989-04-01), DeLuca et al.
patent: 4855144 (1989-08-01), Leong et al.
patent: 4857311 (1989-08-01), Domb et al.
patent: 4865789 (1989-09-01), Castro et al.
patent: 4904479 (1990-02-01), Illum
patent: 5069936 (1991-12-01), Yen
patent: 5145684 (1992-09-01), Liversidge et al.
patent: 5160745 (1992-11-01), DeLuca et al.
patent: 5169871 (1992-12-01), Hughes et al.
patent: 5260306 (1993-11-01), Boradman et al.
patent: 5384133 (1995-01-01), Boyes et al.
patent: 5437873 (1995-08-01), Phadke et al.
patent: 5456917 (1995-10-01), Wise et al.
patent: 5458135 (1995-10-01), Patton et al.
patent: 5506203 (1996-04-01), Bäckström et al.
patent: 5518998 (1996-05-01), Bäckström et al.
patent: 5607695 (1997-03-01), Ek et al.
patent: 5612053 (1997-03-01), Baichwal et al.
patent: 5642728 (1997-07-01), Anderson et al.
patent: 5690954 (1997-11-01), Illum
patent: 5707644 (1998-01-01), Illum
patent: 5780014 (1998-07-01), Eljamal et al.
patent: 5795594 (1998-08-01), York et al.
patent: 5804212 (1998-09-01), Illum
patent: 5830853 (1998-11-01), Bäckström et al.
patent: 5851453 (1998-12-01), Hanna et al.
patent: 5855913 (1999-01-01), Hanes et al.
patent: 5874064 (1999-02-01), Edwards et al.
patent: 5977848 (1999-11-01), Nakaguchi et al.
patent: 5985309 (1999-11-01), Edwards et al.
patent: 6063138 (2000-05-01), Hanna et al.
patent: 6165463 (2000-12-01), Platz et al.
patent: 6254854 (2001-07-01), Edwards et al.
patent: 6372258 (2002-04-01), Platz et al.
patent: 6423344 (2002-07-01), Platz et al.
patent: 6436443 (2002-08-01), Edwards et al.
patent: 6942868 (2005-09-01), Edwards et al.
patent: 6977087 (2005-12-01), Edwards et al.
patent: 0 072 046 (1983-02-01), None
patent: 0 257 915 (1988-03-01), None
patent: 0 335 133 (1989-10-01), None
patent: WO 91/04732 (1991-04-01), None
patent: WO 94/07514 (1994-04-01), None
patent: WO 95/00127 (1995-01-01), None
patent: WO 95/24183 (1995-09-01), None
patent: WO 96/09814 (1996-04-01), None
patent: WO 97/36574 (1997-10-01), None
patent: WO 99/16419 (1999-04-01), None
patent: WO 99/16420 (1999-04-01), None
patent: WO 99/16421 (1999-04-01), None
patent: WO 99/16422 (1999-04-01), None
Merriam Webster's Collegiate Dictionary, 10th Edition, p. 607.
Clay, M.M. et al., “Effect of Aerosol Particle Size on Bronchodilatation with Nebulised Terbutaline in Asthmatic Subjects,”Thorax, 41:364-368 (1986).
Cohen, S. et al., “Controlled Delivery Systems for Proteins Based on Poly(Lactic/Glycolic Acid) Microspheres,”Pharm. Res., 8(6):713-720 (1991).
Daly, W.H., et al., “The Preparation of N-Carboxyanhydrides of α-Amino Acids Using Bis(Trichloromethyl) Carbonate,”Tetrahedron Lett., 29(46):5859-5862 (1988).
Damms, B. and Bains, W., “The Cost of Delivering Drugs without Needles,”J. Controlled Release, 8-11 (1996).
Davies, C.N., et al., “Breathing of Half-micron Aerosols. I. Experimental,”J. of Appl. Physiol., 32(5):591-600 (1972).
Dorries, A.M. and Valberg, P.A., “Heterogeneity of Phagocytosis for Inhaled Versus Instilled Material,”Am. Rev. Respir. Dis., 146:831-837 (1992).
Kricheldorf, H.R., “α-Aminoacid-N-Carboxy-Anhydrides and Related Heterocycles,”Springer-Verlag, Berlin (1987).
Edwards, D.A., “The Macrotransport of Aerosol Particles in the Lung: Aerosol Deposition Phenomena,”J Aerosol Sci, 26(2):293-317 (1995).
Eldridge, J.H., et al., “Biodegradable Microspheres as a Vaccine Delivery System,”Mol Immunol., 28(3):287-294 (1991).
French, D.L., et al., “The Infulence of Formulation on Emission, Deaggregation and Deposition of Dry Powders for Inhalation,”J. Aerosol Sci., 27(5):769-783 (1996).
Ganderton, D., “The Generation of Respirable Clouds from Coarse Powder Aggregates,”J. Biopharmaceutical Sci., 3(1/2):101-105 (1992).
Gehr, P., et al., “Surfactant and Inhaled Particles in the Conducting Airways: Structural, Stereological, and Biophysical Aspects,”Microscopy Res. And Tech., 26:423-436 (1993).
Gerrity, T.R., et al., “Calculated Deposition of Inhaled Particles in the Airway Generations of Normal Subjects,”J. Appl. Phys., 47(4):867-873 (1979).
Moràn, F., Aerosol Dosage Forms and Formulations, InAerosols in Medicine. Principles, Diagnosis and Theraphy, Moren, et al., Eds., Elsevier, Amsterdam, (1985).
Morimoto, Y., and Adachi, Y., “Pulmonary Uptake of Liposomal Phosphatidylcholine Upon Intratracheal Administration to Rats,”Chem Pharm Bull., 30(6):2248-2251 (1982).
Mulligan, R.C., “The Basic Science of Gene Therapy,”Science, 260:926-932 (1993).
Mumenthaler, M., et al., “Feasibility Study on Spray-Drying Protein Pharmaceuticals: Recombinant human Growth Hormone and Tissue-Type Plasminogne Activator,”Pharm Res., 11(1):12-20 (1994).
Niven, R.W., et al., “The Pulmonary Absorption of Aerosolized and Intratracheally Instilled rhG-CSF and monoPEGylated rhG-CSF,”Pharm Res., 12(9):1343-1349 (1995).
Okumura, K., et al., “Intratracheal Delivery of Insulin. Absorption from Solution and Aerosol by Rat Lung,”Int. J. Pharmaceutics, 88:63-73 (1992).
Patton, J.S. and Platz, R.M., “(D) Routes of Delivery: Case Studies (2) Pulmonary Delivery of Peptides and Proteins for Systemic Action,”Adv Drug Del Rev., 8:179-196 (1992).
Patton, J.S., et al., “Bioavailability of pulmonary delivered peptides and proteins: α-interferon, calcitonins and parathyroid hormones,”J Controlled Release, 28:79-85 (1994).
Pavia, D., “Lung Mucociliary Clearance.” InAerosols and the Lung: Clinical and Experimental Aspects, Clarke, S.W. and Pavia, D., eds (Butterworths, London), pp. 127-155 (1984).
Landahl, “On The Removal of Air-borne Droplets by The Human Respiratory Tract: I. The Lung,”Bull. Math. Biophys., 12:43-56 (1950).
Timsina, M.P., et al., “Drug Delivery to the Respiratory Tract Using Dry Powder Inhalers,”Int. J. of Pharm., 101:1-13 (1994).
Adjei, A., and Garren, J., “Pulmonary Delivery of Peptide Drugs: Effect of Particle Size on Bioavailability of Leuprolide Acetate in Healthy Male Volunteers,”Pharm Res., 7(6):565-569 (1990).
Altshuler, B., et al., “Aerosol Deposition in the Human Respiratory Tract,”Am Med Assoc Arch of Indust Health, 15:293-303 (1957).
Anderson, P.J., et al., “Effect of Cystic Fibrosis on Inhaled Aerosol Boluses,”Am Rev Respir Dis., 140:1317-1324 (1989).
Pinkerton, K.E., et al., “Aerosolized Fluorescent Microspheres Detected in the Lung Using Confocal Scanning Laser Microscopy,”Microscopy Res and Tech, 26:437-443 (1993).
Colthorpe, P., et al., “The Pharmacokinetics of Pulmonary-Delivered Insulin: A Comparison of Intratracheal and Aerosol A

Affiliated with

Also associated with

Rating

Porous particles comprising excipients for deep lung delivery does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Porous particles comprising excipients for deep lung delivery, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Porous particles comprising excipients for deep lung delivery will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4003451